The clinical importance of relationship between antibiotic pharmacokinetic/pharmacodynamic parameters in critical ill patients;Signification clinique des corrélations pharmacocinétique/ pharmacodynamie des antibiotiques chez les patients de réanimation

Reanimation

Volumn 14, Issue 4, 2005, Pages 264-275

  Garraffo, R ^a   Lavrut, T ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Antibiotics; Intensive care units; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLOXACILLIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; MACROLIDE; OXACILLIN; PENICILLIN G; PIPERACILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION (PARAMETERS); CRITICAL ILLNESS; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MUTATION;

EID: 20444370317     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2005.04.006     Document Type: Short Survey

References (28)

1. J. Garnacho-Montero, J.L. Garcia-Garmendia, A. Barrero-Almodovar, F.J. Jimenez-Jimenez, C. Perez-Paredes, and C. Ortiz-Leyba Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis Crit. Care Med. 31 2003 2742 2751
2. C.M.H. Gomez, J.J. Cordingly, and M.G. Palazzo Altered pharmacokinetics of ceftazidime in critically ill patients Antimicrob. Agents Chemother. 43 1999 1798 1802
3. R. Sauermann, M. Zeitlinger, B.M. Erovic, C. Marsik, A. Georgopoulos, and M. Muller Pharmacodynamics of piperacillin in severly ill patients evaluated by using a PK/PD model Int J Antimicrob Agents 22 2003 574 578
4. G. Beaucaire Modalit́s d'administration des antibiotiques en ŕanimation Actualit́s en ŕanimation et urgences 2000 Elsevier ́diteur Paris 173 188
5. C. Martin, M.N. Mallet, P. Saux, B. Bruguerolle, V. Herat, and F. Gouin Tobramycin dosing in mechanically ventilated patients inaccuracy of a "rule of thumb" J. Antimicrob. Chemother. 22 1998 505 511
6. M.J. Weinbren, G. Zanetti, and J.D. Baumgartner Pharmacokinetics of antibiotics in burn patients J. Antimicrob. Chemother. 44 3 1999 319 327
7. M.P. Glauser, G. Zanetti, J.D. Baumgartner, and J. Cohen Septic shock: pathogenesis Lancet 338 1991 732 735
8. G. Lugo, and G. Castaneda-Hernandez Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis Crit. Care Med. 25 1997 806 811
9. A. Vuagna, R. Stern, A. Lotthe, H. Schuhmacher, M. Duong, and P. Hoffmeyer High dose vancomycine for osteomyelitis: continuous vs. intermittent infusion J.Clin. Pharm. Ther. 29 2004 351 357
10. B. Vogelman, and W.A. Craig Kinetics of antimicrobial activity J. Pediatr. 108 1986 835 840
11. J.M. Hyatt, P.S. Mckinnon, G.S. Zimmer, and J.J. Schentag The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents Clin. Pharmacokinet. 28 1995 143 160
12. R.D. Moore, P.S. Lietman, and C.R. Smith Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration J. Infect. Dis. 155 1987 93 99
13. A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob. Agents Chemother. 37 1993 1073 1081
14. P.E. Marik Aminoglycoside volume of distribution and illness severity in clinically ill patients Anesth. Intensive Care 21 1993 172 173
15. M. Barza, J.P. Ioannidis, J.C. Cappelleri, and J. Lau Single or multiple daily doses of aminoglycosides: a meta-analysis BMJ 312 1996 338 345
16. S.L. Preston, G.L. Drusano, A.L. Berman, C.L. Fowler, A.T. Chow, and B. Dornseif Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials JAMA 279 1998 125 129
17. J. Lipman, J. Scribante, A.G. Gous, H. Hon, S. Tshukutsoane The Baragwanath Ciprofloxacin Study Group Pharmacokinetic profiles of high dose intravenous ciprofloxacin in severe sepsis Antimicrob Agents Chemother. 42 1998 2235 2239
18. D. Andes, and W.A. Craig Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine tigh and lung infection models Antimicrob. Agents Chemother. 46 2002 1665 1670
19. P.G. Ambrose, D.M. Grasela, T.H. Grasela, J. Passarell, H.B. Mayer, and P.F. Pierce Pharmacodynamics of fluoroquinolones against Streprococcus pneumoniae in patients with community acquired respiratory tract infections Antimicrob. Agents Chemother. 45 2001 2793 2797
20. J.K. Thomas, A. Forrest, S.M. Bhavnami, J.M. Hyatt, A. Cheng, and C.H. Ballow Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy Antimicrob. Agents Chemother. 42 1998 521 527
21. J.J. Schentag, A.K. Meagher, and A. Forrest Fluoroquinolone AUIC break points and the link to bacterial killing rates: Human Trials Ann. Pharmacother. 37 2003 1478 1488
22. Y. Dong, X. Zhao, J. Domagala, and K. Drlica Effect of fluoroquinolone concentration on selection of resistant mutant of Mycobacterium bovis BCG and Staphylococcus aureus Antimicrob. Agents Chemother. 43 1999 1756 1758
23. J.M. Hyatt, and J.J. Schentag Pharmacodynamic modelling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa Infect. Control Hosp. Epidemiol. suppl. 2000 S9 S11
24. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin. Infect. Dis. 26 1998 1 12
25. W.A. Craig Does the dose matter? CID 33 suppl 3 2001 S233 S237
26. R. Garraffo Bases pharmacodynamiques de l'administration IV des β lactamines par perfusion continue:: optimisation de l'activit́ antibact́rienne sur les bacilles ̀ Gram ńgatif Antibiot. 4 2002 22 27
27. M. Manduru, L.B. Mihm, R.L. White, L.W. Friedrich, R.A. Flume, and J.A. Bosso In vitro pharmacodynamics of ceftazidime against P. aeruginosa isolates from cystic fibrosis patients Antimicrob. Agents Chemother. 41 1997 2053 2056
28. M. Wysocki, F. Delatour, F. Faurisson, A. Rauss, Y. Pean, and B. Misset Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study Antimicrob. Agents Chemother. 45 2001 2460 2467